Document:

Exhibit 10.5

 

Biotech Acquisition Company 

545
West 25th Street, 20th Floor

New
York, NY 10001

 

September 8, 2020 

 

Biotech Sponsor LLC

545 West 25th Street,
20th Floor

New York, NY 10001

 

RE: Securities Subscription Agreement

 

Ladies and Gentlemen:

 

This agreement (the
“Agreement”) is entered into on September 8, 2020 by and between Biotech Sponsor LLC, a Delaware limited liability
company (the “Subscriber” or “you”), and Biotech Acquisition Company, a Cayman Islands exempted
company (the “Company,” “we” or “us”). Pursuant to the terms hereof, the
Company hereby accepts the offer the Subscriber has made to purchase 5,750,000 Class B ordinary shares, $0.0001 par value per share
(the “Shares”), up to 750,000 of which are subject to forfeiture by you if the underwriters of the initial public
offering (“IPO”) of units (“Units”) of the Company, do not fully exercise their over-allotment
option (the “Over-allotment Option”). The Company and the Subscriber’s agreements regarding such Shares
are as follows:

 

1. Purchase
of Shares.

 

1.1
Subscription and Purchase of Shares. For the sum of $25,000 (the “Purchase Price”), which the Company
acknowledges receiving in the form of a capital contribution, the Company hereby issues the Shares to the Subscriber, and the Subscriber
hereby subscribes for and purchases the Shares from the Company, 750,000 of which are subject to forfeiture, on the terms and subject
to the conditions set forth in this Agreement. All references in this Agreement to shares of the Company being forfeited shall
take effect as surrenders for no consideration of such shares as matter of Cayman Islands law.

 

1.2
Surrender of Class B Ordinary Share. Upon the issue of the Shares, the Subscriber hereby surrenders to the Company for no
consideration the one Class B ordinary share held by the Subscriber following the incorporation of the Company.

 

2. Representations,
Warranties and Agreements.

 

2.1. Subscriber’s
Representations, Warranties and Agreements. To induce the Company to issue the Shares to the Subscriber, the Subscriber hereby
represents and warrants to the Company and agrees with the Company as follows:

 

2.1.1. No
Government Recommendation or Approval. The Subscriber understands that no federal or state agency has passed upon or made any
recommendation or endorsement of the offering of the Shares.

 

2.1.2. No
Conflicts. The execution, delivery and performance of this Agreement and the consummation by the Subscriber of the transactions
contemplated hereby do not violate, conflict with or constitute a default under (i) the formation and governing documents of the
Subscriber, (ii) any agreement, indenture or instrument to which the Subscriber is a party or (iii) any law, statute, rule or regulation
to which the Subscriber is subject, or any agreement, order, judgment or decree to which the Subscriber is subject.

 

2.1.3. Organization
and Authority. The Subscriber is a Delaware limited liability company, validly existing and in good standing under the laws
of Delaware and possesses all requisite power and authority necessary to carry out the transactions contemplated by this Agreement.
Upon execution and delivery by you, this Agreement is a legal, valid and binding agreement of Subscriber, enforceable against Subscriber
in accordance with its terms, except as such enforceability may be limited by applicable bankruptcy, insolvency, fraudulent conveyance
or similar laws affecting the enforcement of creditors’ rights generally and subject to general principles of equity (regardless
of whether enforcement is sought in a proceeding at law or in equity).

 

    	 	1	 

     

    

 

2.1.4. Experience,
Financial Capability and Suitability. Subscriber is: (i) sophisticated in financial matters and is able to evaluate the risks
and benefits of the investment in the Shares and (ii) able to bear the economic risk of its investment in the Shares for an indefinite
period of time because the Shares have not been registered under the Securities Act (as defined below) and therefore cannot be
sold unless subsequently registered under the Securities Act or an exemption from such registration is available. Subscriber is
capable of evaluating the merits and risks of its investment in the Company and has the capacity to protect its own interests.
Subscriber must bear the economic risk of this investment until the Shares are sold pursuant to: (i) an effective registration
statement under the Securities Act or (ii) an exemption from registration available with respect to such sale. Subscriber is able
to bear the economic risks of an investment in the Shares and to afford a complete loss of Subscriber’s investment in the
Shares.

 

2.1.5. Access
to Information; Independent Investigation. Prior to the execution of this Agreement, the Subscriber has had the opportunity
to ask questions of and receive answers from representatives of the Company concerning an investment in the Company, as well as
the finances, operations, business and prospects of the Company, and the opportunity to obtain additional information to verify
the accuracy of all information so obtained. In determining whether to make this investment, Subscriber has relied solely on Subscriber’s
own knowledge and understanding of the Company and its business based upon Subscriber’s own due diligence investigation and
the information furnished pursuant to this paragraph. Subscriber understands that no person has been authorized to give any information
or to make any representations which were not furnished pursuant to this Section 2 and Subscriber has not relied on any other representations
or information in making its investment decision, whether written or oral, relating to the Company, its operations and/or its prospects.

 

2.1.6. Regulation
D Offering. Subscriber represents that it is an “accredited investor” as such term is defined in Rule 501(a) of
Regulation D under the Securities Act of 1933, as amended (the “Securities Act”) and acknowledges the sale contemplated
hereby is being made in reliance on a private placement exemption to “accredited investors” within the meaning of Section
501(a) of Regulation D under the Securities Act or similar exemptions under state law.

 

2.1.7. Investment
Purposes. The Subscriber is purchasing the Shares solely for investment purposes, for the Subscriber’s own account and
not for the account or benefit of any other person, and not with a view towards the distribution or dissemination thereof. The
Subscriber did not decide to enter into this Agreement as a result of any general solicitation or general advertising within the
meaning of Rule 502 under the Securities Act.

 

2.1.8. Restrictions
on Transfer; Shell Company. Subscriber understands the Shares are being offered in a transaction not involving a public offering
within the meaning of the Securities Act. Subscriber understands the Shares will be “restricted securities” within
the meaning of Rule 144(a)(3) under the Securities Act, and Subscriber understands that the certificates or book-entries representing
the Shares will contain a legend in respect of such restrictions. If in the future the Subscriber decides to offer, resell, pledge
or otherwise transfer the Shares, such Shares may be offered, resold, pledged or otherwise transferred only pursuant to: (i) registration
under the Securities Act, or (ii) an available exemption from registration. Subscriber agrees that if any transfer of its Shares
or any interest therein is proposed to be made, as a condition precedent to any such transfer, Subscriber may be required to deliver
to the Company an opinion of counsel satisfactory to the Company. Absent registration or an exemption, the Subscriber agrees not
to resell the Shares. Subscriber further acknowledges that because the Company is a shell company, Rule 144 may not be available
to the Subscriber for the resale of the Shares until one year following consummation of the initial business combination of the
Company, despite technical compliance with the requirements of Rule 144 and the release or waiver of any contractual transfer restrictions.

 

2.1.9. No
Governmental Consents. No governmental, administrative or other third party consents or approvals are required, necessary or
appropriate on the part of Subscriber in connection with the transactions contemplated by this Agreement.

 

2.2 Company’s
Representations, Warranties and Agreements. To induce the Subscriber to purchase the Shares, the Company hereby represents
and warrants to the Subscriber and agrees with the Subscriber as follows: 

 

    	 	2	 

     

    

 

2.2.1 Incorporation
and Corporate Power. The Company is a Cayman Islands exempted company and is qualified to do business in every jurisdiction
in which the failure to so qualify would reasonably be expected to have a material adverse effect on the financial condition, operating
results or assets of the Company. The Company possesses all requisite corporate power and authority necessary to carry out the
transactions contemplated by this Agreement. 

 

2.2.2. No
Conflicts. The execution, delivery and performance of this Agreement and the consummation by the Company of the transactions
contemplated hereby do not violate, conflict with or constitute a default under (i) the memorandum and articles of association
of the Company, (ii) any agreement, indenture or instrument to which the Company is a party, (iii) any law, statute, rule or regulation
to which the Company is subject, or (iv) any agreement, order, judgment or decree to which the Company is subject. 

 

2.2.3. Title
to Securities. Upon issuance in accordance with, and payment pursuant to, the terms hereof, and registration in the Company’s
register of members, the Shares will be duly and validly issued, fully paid and non-assessable. Upon issuance in accordance with,
and payment pursuant to, the terms hereof, and registration in the Company’s register of members, the Subscriber will have
or receive good title to the Shares, free and clear of all liens, claims and encumbrances of any kind, other than (a) transfer
restrictions hereunder and other agreements to which the Shares may be subject which have been notified to the Subscriber in writing,
(b) transfer restrictions under federal and state securities laws, and (c) liens, claims or encumbrances imposed due to the actions
of the Subscriber. 

 

2.2.4. No
Adverse Actions. There are no actions, suits, investigations or proceedings pending, threatened against or affecting the Company
which: (i) seek to restrain, enjoin, prevent the consummation of or otherwise affect the transactions contemplated by this Agreement
or (ii) question the validity or legality of any transactions or seeks to recover damages or to obtain other relief in connection
with any transactions.

 

3. Forfeiture
of Shares.

 

3.1. Partial
or No Exercise of the Over-allotment Option. In the event the Over-allotment Option granted to the underwriters of the IPO
is not exercised in full, the Subscriber acknowledges and agrees that it (or, if applicable, it and any transferees of Shares)
shall forfeit any and all rights to such number of Shares (up to an aggregate of 750,000 Shares and pro rata based upon the percentage
of the Over-allotment Option exercised) such that immediately following such forfeiture, the Subscriber (and all other initial
shareholders prior to the IPO, if any) will own an aggregate number of Shares, not including Shares issuable upon exercise of any
warrants or any Ordinary Shares purchased by Subscriber in the IPO or in the aftermarket equal to 20% of the issued and outstanding
Shares immediately following the IPO.

 

3.2. Termination
of Rights as Shareholder. If any of the Shares are forfeited in accordance with this Section 3, then after such time the Subscriber
(or successor in interest), shall no longer have any rights as a holder of such forfeited Shares, and the Company shall take such
action as is appropriate to cancel such forfeited Shares.

 

4. Waiver
of Liquidation Distributions; Redemption Rights. In connection with the Shares purchased pursuant to this Agreement, the Subscriber
hereby waives any and all right, title, interest or claim of any kind in or to any distributions by the Company from the trust
account which will be established for the benefit of the Company’s public shareholders and into which substantially all of
the proceeds of the IPO will be deposited (the “Trust Account”), in the event of a liquidation of the Company
upon the Company’s failure to timely complete an initial business combination. For purposes of clarity, in the event the
Subscriber purchases Shares in the IPO or in the aftermarket, any additional Shares so purchased shall be eligible to receive any
liquidating distributions by the Company. However, in no event will the Subscriber have the right to redeem any Shares into funds
held in the Trust Account upon the successful completion of an initial business combination.

 

5. Restrictions
on Transfer.

 

5.1. Securities
Law Restrictions. In addition to any restrictions to be contained in that certain letter agreement (commonly known as an “Insider
Letter”) to be dated as of the closing of the IPO by and between Subscriber and the Company, Subscriber agrees not to
sell, transfer, pledge, hypothecate or otherwise dispose of all or any part of the Shares unless, prior thereto (a) a registration
statement on the appropriate form under the Securities Act and applicable state securities laws with respect to the Shares proposed
to be transferred shall then be effective or (b) the Company has received an opinion from counsel reasonably satisfactory to the
Company, that such registration is not required because such transaction is exempt from registration under the Securities Act and
the rules promulgated by the Securities and Exchange Commission thereunder and with all applicable state securities laws. 

 

    	 	3	 

     

    

 

5.2. Lock-up.
Subscriber acknowledges that the Securities will be subject to lock-up provisions (the “Lock-up”) contained
in the Insider Letter.

 

5.3. Restrictive
Legends. Any certificates representing the Shares shall have endorsed thereon legends substantially as follows:

 

“THE SECURITIES REPRESENTED HEREBY
HAVE NOT BEEN REGISTERED UNDER THE UNITED STATES SECURITIES ACT OF 1933, AS AMENDED, OR ANY STATE SECURITIES LAWS AND NEITHER THE
SECURITIES NOR ANY INTEREST THEREIN MAY BE OFFERED, SOLD, TRANSFERRED, PLEDGED OR OTHERWISE DISPOSED OF EXCEPT PURSUANT TO AN EFFECTIVE
REGISTRATION STATEMENT UNDER SUCH ACT OR SUCH LAWS OR AN EXEMPTION FROM REGISTRATION UNDER SUCH ACT AND SUCH LAWS WHICH, IN THE
OPINION OF COUNSEL, IS AVAILABLE.”

 

“THE SECURITIES REPRESENTED BY THIS
CERTIFICATE ARE SUBJECT TO A LOCKUP AND MAY NOT BE OFFERED, SOLD, TRANSFERRED, PLEDGED OR OTHERWISE DISPOSED DURING THE TERM OF
THE LOCKUP.”

 

5.4. Additional
Shares or Substituted Securities. In the event of the declaration of a share capitalization, the declaration of an extraordinary
dividend payable in a form other than Shares, a spin-off, a share sub-division, an adjustment in conversion ratio, a recapitalization
or a similar transaction affecting the Company’s outstanding Shares without receipt of consideration, any new, substituted
or additional securities or other property which are by reason of such transaction distributed with respect to any Shares subject
to this Section 5 or into which such Shares thereby become convertible shall immediately be subject to this Section 5 and Section
3. Appropriate adjustments to reflect the distribution of such securities or property shall be made to the number and/or class
of Shares subject to this Section 5 and Section 3.

 

5.5. Registration
Rights. Subscriber acknowledges that the Shares are being purchased pursuant to an exemption from the registration requirements
of the Securities Act and will become freely tradable only after certain conditions are met or they are registered pursuant to
a registration rights agreement to be entered into with the Company prior to the closing of the IPO.

 

6. Other
Agreements.

 

6.1. Further
Assurances. Subscriber agrees to execute such further instruments and to take such further action as may reasonably be necessary
to carry out the intent of this Agreement.

 

6.2. Notices.
All notices, statements or other documents which are required or contemplated by this Agreement shall be: (i) in writing and delivered
personally or sent by first class registered or certified mail, overnight courier service or facsimile or electronic transmission
to the address designated in writing, (ii) by facsimile to the number most recently provided to such party or such other address
or fax number as may be designated in writing by such party and (iii) by electronic mail, to the electronic mail address most recently
provided to such party or such other electronic mail address as may be designated in writing by such party. Any notice or other
communication so transmitted shall be deemed to have been given on the day of delivery, if delivered personally, on the business
day following receipt of written confirmation, if sent by facsimile or electronic transmission, one (1) business day after delivery
to an overnight courier service or five (5) days after mailing if sent by mail.

 

6.3. Entire
Agreement. This Agreement, together with the Insider Letter and the Registration Rights Agreement, each substantially in the
form to be filed as an exhibit to the Registration Statement on Form S-1 associated with the Company’s IPO, embodies the
entire agreement and understanding between the Subscriber and the Company with respect to the subject matter hereof and supersedes
all prior oral or written agreements and understandings relating to the subject matter hereof. No statement, representation, warranty,
covenant or agreement of any kind not expressly set forth in this Agreement shall affect, or be used to interpret, change or restrict,
the express terms and provisions of this Agreement. 

 

    	 	4	 

     

    

 

6.4. Modifications
and Amendments. The terms and provisions of this Agreement may be modified or amended only by written agreement executed by
all parties hereto.

 

6.5. Waivers
and Consents. The terms and provisions of this Agreement may be waived, or consent for the departure therefrom granted, only
by a written document executed by the party entitled to the benefits of such terms or provisions. No such waiver or consent shall
be deemed to be or shall constitute a waiver or consent with respect to any other terms or provisions of this Agreement, whether
or not similar. Each such waiver or consent shall be effective only in the specific instance and for the purpose for which it was
given, and shall not constitute a continuing waiver or consent.

 

6.6. Assignment.
The rights and obligations under this Agreement may not be assigned by either party hereto without the prior written consent of
the other party.

 

6.7. Benefit.
All statements, representations, warranties, covenants and agreements in this Agreement shall be binding on the parties hereto
and shall inure to the benefit of the respective successors and permitted assigns of each party hereto. Nothing in this Agreement
shall be construed to create any rights or obligations except among the parties hereto, and no person or entity shall be regarded
as a third-party beneficiary of this Agreement.

 

6.8. Governing
Law. This Agreement and the rights and obligations of the parties hereunder shall be construed in accordance with and governed
by the laws of New York applicable to contracts wholly performed within the borders of such state, without giving effect to the
conflict of law principles thereof.

 

6.9. Severability.
In the event that any court of competent jurisdiction shall determine that any provision, or any portion thereof, contained in
this Agreement shall be unreasonable or unenforceable in any respect, then such provision shall be deemed limited to the extent
that such court deems it reasonable and enforceable, and as so limited shall remain in full force and effect. In the event that
such court shall deem any such provision, or portion thereof, wholly unenforceable, the remaining provisions of this Agreement
shall nevertheless remain in full force and effect.

 

6.10. No
Waiver of Rights, Powers and Remedies. No failure or delay by a party hereto in exercising any right, power or remedy under
this Agreement, and no course of dealing between the parties hereto, shall operate as a waiver of any such right, power or remedy
of such party. No single or partial exercise of any right, power or remedy under this Agreement by a party hereto, nor any abandonment
or discontinuance of steps to enforce any such right, power or remedy, shall preclude such party from any other or further exercise
thereof or the exercise of any other right, power or remedy hereunder. The election of any remedy by a party hereto shall not constitute
a waiver of the right of such party to pursue other available remedies. No notice to or demand on a party not expressly required
under this Agreement shall entitle the party receiving such notice or demand to any other or further notice or demand in similar
or other circumstances or constitute a waiver of the rights of the party giving such notice or demand to any other or further action
in any circumstances without such notice or demand.

 

6.11. Survival
of Representations and Warranties. All representations and warranties made by the parties hereto in this Agreement or in any
other agreement, certificate or instrument provided for or contemplated hereby, shall survive the execution and delivery hereof
and any investigations made by or on behalf of the parties.

 

6.12. No
Broker or Finder. Each of the parties hereto represents and warrants to the other that no broker, finder or other financial
consultant has acted on its behalf in connection with this Agreement or the transactions contemplated hereby in such a way as to
create any liability on the other. Each of the parties hereto agrees to indemnify and save the other harmless from any claim or
demand for commission or other compensation by any broker, finder, financial consultant or similar agent claiming to have been
employed by or on behalf of such party and to bear the cost of legal expenses incurred in defending against any such claim.

 

6.13. Headings
and Captions. The headings and captions of the various subdivisions of this Agreement are for convenience of reference only
and shall in no way modify or affect the meaning or construction of any of the terms or provisions hereof.

 

    	 	5	 

     

    

 

6.14. Counterparts.
This Agreement may be executed in one or more counterparts, all of which when taken together shall be considered one and the same
agreement and shall become effective when counterparts have been signed by each party and delivered to the other party, it being
understood that both parties need not sign the same counterpart. In the event that any signature is delivered by facsimile transmission
or any other form of electronic delivery, such signature shall create a valid and binding obligation of the party executing (or
on whose behalf such signature is executed) with the same force and effect as if such signature page were an original thereof.

 

6.15. Construction.
The parties hereto have participated jointly in the negotiation and drafting of this Agreement. If an ambiguity or question of
intent or interpretation arises, this Agreement will be construed as if drafted jointly by the parties hereto and no presumption
or burden of proof will arise favoring or disfavoring any party hereto because of the authorship of any provision of this Agreement.
The words “include,” “includes,” and “including” will be deemed to be
followed by “without limitation.” Pronouns in masculine, feminine, and neuter genders will be construed to include
any other gender, and words in the singular form will be construed to include the plural and vice versa, unless the context otherwise
requires. The words “this Agreement,” “herein,” “hereof,” “hereby,”
“hereunder,” and words of similar import refer to this Agreement as a whole and not to any particular subdivision
unless expressly so limited. The parties hereto intend that each representation, warranty, and covenant contained herein will have
independent significance. If any party hereto has breached any representation, warranty, or covenant contained herein in any respect,
the fact that there exists another representation, warranty or covenant relating to the same subject matter (regardless of the
relative levels of specificity) which such party hereto has not breached will not detract from or mitigate the fact that such party
hereto is in breach of the first representation, warranty, or covenant.

 

6.16. Mutual
Drafting. This Agreement is the joint product of the Subscriber and the Company and each provision hereof has been subject
to the mutual consultation, negotiation and agreement of such parties and shall not be construed for or against any party hereto.

 

7. Voting
and Tender of Shares. Subscriber agrees to vote the Shares in favor of an initial business combination that the Company negotiates
and submits for approval to the Company’s shareholders and shall not seek redemption or repurchase with respect to such Shares.
Additionally, the Subscriber agrees not to tender any Shares in connection with a tender offer presented to the Company’s
shareholders in connection with an initial business combination negotiated by the Company.

 

8.  Indemnification.
Each party shall indemnify the other against any loss, cost or damages (including reasonable attorney’s fees and expenses)
incurred as a result of such party’s breach of any representation, warranty, covenant or agreement in this Agreement.

 

[Signature Page Follows]

 

    	 	6	 

     

    

 

If the foregoing accurately
sets forth our understanding and agreement, please sign the enclosed copy of this Agreement and return it to us.

 

	 	Very truly yours,
	 	 
	 	BIOTECH ACQUISITION COMPANY
	 	 	 
	 	By:	/s/ Albert Hummel 
	 	 	Name: Albert Hummel 
	 	 	Title:  Director

 

	Accepted and agreed as of the date first written above.	 
	 	 
	BIOTECH SPONSOR LLC	 
	 	 
	By:	
        /s/ Albert Hummel
	

	 	
        Name: Albert Hummel

        Title: Manager
	 

 

[Signature Page to Securities Subscription
Agreement]

 

 

7Exhibit 10.6

 

PRIVATE
PLACEMENT WARRANTS PURCHASE AGREEMENT

 

THIS
PRIVATE PLACEMENT WARRANTS PURCHASE AGREEMENT, dated as of [________], 2021 (as it may from time to time be amended, this “Agreement”),
is entered into by and between Biotech Acquisition Company, a Cayman Islands exempted company (the “Company”),
and Biotech Sponsor LLC, a Delaware limited liability company (the “Purchaser”).

 

WHEREAS,
the Company is a blank check formed for the purpose of acquiring one or more businesses or entities (a “Business Combination”);

 

WHEREAS,
the Company intends to consummate an initial public offering of the Company’s units (the “Public Offering”),
with each unit (each, a “Unit”) consisting of one Class A ordinary share of the Company, par value $0.001 per
ordinary share (each, a “Share”), and one-half of one redeemable warrant, with each whole warrant, (each, a
“Warrant”) entitling the holder to purchase one Share at an exercise price of $11.50 per Share; and

 

WHEREAS,
the Purchaser has agreed to purchase, at a price of $1.00 per Warrant, an aggregate of 6,000,000 Warrants (the “Private
Placement Warrants”), with each Private Placement Warrant consisting of one Share and one-half of one Warrant.

 

NOW
THEREFORE, in consideration of the mutual promises contained in this Agreement and other good and valuable consideration, the
receipt and sufficiency of which are hereby acknowledged, the parties to this Agreement hereby, intending legally to be bound,
agree as follows:

 

AGREEMENT

 

		1.	Authorization,
                                         Purchase and Sale; Terms of the Private Placement Warrants.

 

		(a)	Authorization
                                         of the Private Placement Warrants. The Company has duly authorized the issuance and
                                         sale of the Private Placement Warrants to the Purchaser.

 

		(b)	Purchase
                                         and Sale of the Private Placement Warrants. Simultaneously with the consummation
                                         of the Public Offering or on such earlier time and date as may be mutually agreed by
                                         the Purchaser and the Company (the “Closing Date”), the Company shall
                                         issue and sell to the Purchaser, and the Purchaser shall purchase from the Company, an
                                         aggregate of 6,000,000 Private Placement Warrants at a price of $1.00 per Warrant for
                                         an aggregate purchase price of $6,000,000 (the “Purchase Price”).
                                         Purchaser shall pay the Purchase Price by wire transfer of immediately available funds
                                         to the trust account maintained by Continental Stock Transfer & Trust Company, acting
                                         as trustee, at least one business day prior to the date of effectiveness (the “Effective
                                         Date”) of the registration statement relating to the Public Offering (the “Registration
                                         Statement”). On the Closing Date, upon the payment by the Purchaser of the
                                         Purchase Price, the Company, at its option, shall deliver a certificate evidencing the
                                         Private Placement Warrants purchased on such date duly registered in the Purchaser’s
                                         name to the Purchaser or effect such delivery in book-entry form.

 

		(c)	Terms
                                         of the Private Placement Warrants. The Private Placement Warrants shall have their
                                         terms set forth in a Warrant Agreement entered into by the Company and a warrant agent,
                                         in connection with the Public Offering (a “Warrant Agreement”). At
                                         or prior to the time of the Initial Closing Date, the Company and the Purchaser shall
                                         enter into a registration rights agreement (the “Registration Rights Agreement”)
                                         pursuant to which the Company will grant certain registration rights to the Purchaser
                                         relating to the Sponsor Warrants and the Shares underlying the Sponsor Warrants.

 

     

     

    

 

		2.	Representations
                                         and Warranties of the Company. As a material inducement to the Purchaser to enter
                                         into this Agreement and purchase the Private Placement Warrants, the Company hereby represents
                                         and warrants to the Purchaser (which representations and warranties shall survive each
                                         Closing Date) that:

 

		(a)	Incorporation
                                         and Corporate Power. The Company is an exempted company duly incorporated, validly
                                         existing and in good standing under the laws of the Cayman Islands and is qualified to
                                         do business in every jurisdiction in which the failure to so qualify would reasonably
                                         be expected to have a material adverse effect on the financial condition, operating results
                                         or assets of the Company. The Company possesses all requisite corporate power and authority
                                         necessary to carry out the transactions contemplated by this Agreement.

 

		(b)	Authorization;
                                         No Breach.

 

		(i)	The
                                         execution, delivery and performance of this Agreement and the Private Placement Warrants
                                         have been duly authorized by the Company as of the Closing Date. This Agreement constitutes
                                         the valid and binding obligation of the Company, enforceable in accordance with its terms.
                                         Upon issuance in accordance with, and payment pursuant to, the terms of this Agreement,
                                         the Private Placement Warrants (and underlying securities) will constitute valid and
                                         binding obligations of the Company, enforceable in accordance with their terms as of
                                         the Closing Dates.

 

		(ii)	The
                                         execution and delivery by the Company of this Agreement and the Private Placement Warrants,
                                         the issuance and sale of the Private Placement Warrants and compliance with, the respective
                                         terms hereof by the Company, do not and will not as of the Closing Date: (A) conflict
                                         with or result in a breach of the terms, conditions or provisions of, (B) constitute
                                         a default under, (C) result in the creation of any lien, security interest, charge or
                                         encumbrance upon the Company’s share capital or assets under, (D) result in a violation
                                         of, or (E) require any authorization, consent, approval, exemption or other action by
                                         or notice or declaration to, or filing with, any court or administrative or governmental
                                         body or agency pursuant to the memorandum and articles of association of the Company
                                         (in effect on the date hereof or as may be amended prior to completion of the contemplated
                                         Public Offering), or any material law, statute, rule or regulation to which the Company
                                         is subject, or any agreement, order, judgment or decree to which the Company is subject,
                                         except for any filings required after the date hereof under federal or state securities
                                         laws.

 

		(iii)	Title
                                         to Securities. Upon issuance in accordance with and payment pursuant to the terms
                                         hereof memorandum and articles of association of the Company and registration in the
                                         register of members of the Company, the Private Placement Warrants will be duly and validly
                                         issued as fully paid and non-assessable. On the date of issuance of the Private Placement
                                         Warrants shall have been reserved for issuance. Upon issuance in accordance with, and
                                         payment pursuant to, the terms hereof, the Purchaser will have good title to the Private
                                         Placement Warrants, free and clear of all liens, claims and encumbrances of any kind,
                                         other than (A) transfer restrictions hereunder and under the other agreements contemplated
                                         hereby, (B) transfer restrictions under federal and state securities laws, and (C) liens,
                                         claims or encumbrances imposed due to the actions of the Purchaser.

 

    - 2 -

     

    

 

		(c)	Governmental
                                         Consents. No permit, consent, approval or authorization of, or declaration to or
                                         filing with, any governmental authority is required in connection with the execution,
                                         delivery and performance by the Company of this Agreement or the consummation by the
                                         Company of any other transactions contemplated hereby.

 

		(d)	Regulation
                                         D Qualification. Neither the Company nor, to its actual knowledge, any of its officers,
                                         directors or beneficial shareholders of 20% or more of its outstanding securities, has
                                         experienced a disqualifying event as enumerated pursuant to Rule 506(d) of Regulation
                                         D promulgated under the Securities Act of 1933, as amended (the “Securities
                                         Act”).

 

		3.	Representations
                                         and Warranties of the Purchaser. As a material inducement to the Company to enter
                                         into this Agreement and issue and sell the Private Placement Warrants to the Purchaser,
                                         the Purchaser hereby represents and warrants to the Company (which representations and
                                         warranties shall survive each Closing Date) that:

 

		(a)	Organization
                                         and Requisite Authority. The Purchaser is a limited liability company duly formed,
                                         validly existing, and in good standing under the laws of the State of Delaware and is
                                         qualified to do business in every jurisdiction in which the failure to so qualify would
                                         reasonably be expected to have a material adverse effect on the financial condition,
                                         operating results or assets of the Purchaser. The Purchaser possesses all requisite limited
                                         liability company power and authority necessary to carry out the transactions contemplated
                                         by this Agreement.

 

		(b)	Authorization;
                                         No Breach.

 

		(i)	This
                                         Agreement constitutes a valid and binding obligation of the Purchaser, enforceable in
                                         accordance with its terms, subject to bankruptcy, insolvency, fraudulent conveyance,
                                         reorganization, moratorium and other laws of general applicability relating to or affecting
                                         creditors’ rights and to general equitable principles (whether considered in a
                                         proceeding in equity or law).

 

		(ii)	The
                                         execution and delivery by the Purchaser of this Agreement and the fulfillment of and
                                         compliance with the terms hereof by the Purchaser does not and shall not as of each Closing
                                         Date conflict with or result in a breach by the Purchaser of the terms, conditions or
                                         provisions of any agreement, instrument, order, judgment or decree to which the Purchaser
                                         is subject.

 

		(c)	Investment
                                         Representations.

 

		(i)	The
                                         Purchaser is acquiring the Private Placement Warrants, for the Purchaser’s own
                                         account, for investment purposes only and not with a view towards, or for resale in connection
                                         with, any public sale or distribution thereof.

 

		(ii)	The
                                         Purchaser is an “accredited investor” as such term is defined in Rule 501(a)(3)
                                         of Regulation D promulgated under the Securities Act and the Purchaser has not experienced
                                         a disqualifying event as enumerated pursuant to Rule 506(d) of Regulation D promulgated
                                         under the Securities Act.

 

    - 3 -

     

    

 

		(iii)	The
                                         Purchaser understands that the Private Placement Warrants are being offered and will
                                         be sold to the Purchaser in reliance on specific exemptions from the registration requirements
                                         of the United States federal and state securities laws and that the Company is relying
                                         upon the truth and accuracy of, and the Purchaser’s compliance with, the representations
                                         and warranties of the Purchaser set forth herein in order to determine the availability
                                         of such exemptions and the eligibility of the Purchaser to acquire such Private Placement
                                         Warrants.

 

		(iv)	The
                                         Purchaser decided to enter into this Agreement not as a result of any general solicitation
                                         or general advertising within the meaning of Rule 502(c) of Regulation D promulgated
                                         under the Securities Act.

 

		(v)	The
                                         Purchaser has been furnished with all materials relating to the business, finances and
                                         operations of the Company and materials relating to the offer and sale of the Private
                                         Placement Warrants which have been requested by the Purchaser. The Purchaser has been
                                         afforded the opportunity to ask questions of the executive officers and directors of
                                         the Company. The Purchaser understands that its investment in the Private Placement Warrants
                                         involves a high degree of risk and it has sought such accounting, legal and tax advice
                                         as it has considered necessary to make an informed investment decision with respect to
                                         the acquisition of the Private Placement Warrants.

 

		(vi)	The
                                         Purchaser understands that no United States federal or state agency or any other government
                                         or governmental agency has passed on or made any recommendation or endorsement of the
                                         Private Placement Warrants or the fairness or suitability of the investment in the Private
                                         Placement Warrants by the Purchaser nor have such authorities passed upon or endorsed
                                         the merits of the offering of the Private Placement Warrants.

 

		(vii)	The
                                         Purchaser understands that: (A) the offer and sale of the Private Placement Warrants
                                         has not been and is not being registered under the Securities Act or any state securities
                                         laws, and may not be offered for sale, sold, assigned or transferred unless (1) the offer
                                         and sale of the Private Placement Warrants is subsequently registered thereunder or (2)
                                         sold in reliance on an exemption therefrom; and (B) except as specifically set forth
                                         in the Registration Rights Agreement, neither the Company nor any other person is under
                                         any obligation to register the offer and sale of the Private Placement Warrants under
                                         the Securities Act or any state securities laws or to comply with the terms and conditions
                                         of any exemption thereunder. The Private Placement Warrants will bear a legend and appropriate
                                         “stop transfer” instructions (or an appropriate notation if securities are
                                         issued in book entry form) relating to the foregoing. The Purchaser further understands
                                         that the Securities and Exchange Commission has taken the position that promoters or
                                         affiliates of a blank check company and their transferees, both before and after an initial
                                         Business Combination, are deemed to be “underwriters” under the Securities
                                         Act when reselling the securities of a blank check company. Based on that position, Rule
                                         144 adopted pursuant to the Securities Act would not be available for resale transactions
                                         of the Private Placement Warrants until the 1-year anniversary following consummation
                                         of an Business Combination despite technical compliance with the requirements of Rule
                                         144.

 

    - 4 -

     

    

 

		(viii)	The
                                         Purchaser has such knowledge and experience in financial and business matters, knows
                                         of the high degree of risk associated with investments in the securities of companies
                                         in the development stage such as the Company, is capable of evaluating the merits and
                                         risks of an investment in the Private Placement Warrants and is able to bear the economic
                                         risk of an investment in the Private Placement Warrants in the amount contemplated hereunder
                                         for an indefinite period of time. The Purchaser has adequate means of providing for its
                                         current financial needs and contingencies and will have no current or anticipated future
                                         needs for liquidity which would be jeopardized by the investment in the Private Placement
                                         Warrants. The Purchaser can afford a complete loss of its investment in the Private Placement
                                         Warrants.

 

		4.	Conditions
                                         of the Purchaser’s Obligations. The obligations of the Purchaser to purchase
                                         and pay for the Private Placement Warrants are subject to the fulfillment, on or before
                                         each Closing Date, of each of the following conditions:

 

		(a)	Representations
                                         and Warranties. The representations and warranties of the Company contained in Section
                                         2 shall be true and correct at and as of such Closing Date as though then made.

 

		(b)	Performance.
                                         The Company shall have performed and complied with all agreements, obligations and conditions
                                         contained in this Agreement that are required to be performed or complied with by it
                                         on or before such Closing Date.

 

		(c)	No
                                         Injunction. No litigation, statute, rule, regulation, executive order, decree, ruling
                                         or injunction shall have been enacted, entered, promulgated or endorsed by or in any
                                         court or governmental authority of competent jurisdiction or any self-regulatory organization
                                         having authority over the matters contemplated hereby, which prohibits the consummation
                                         of any of the transactions contemplated by this Agreement.

 

		(d)	Registration
                                         Rights Agreement. The Company shall have entered into a registration rights agreement
                                         on terms satisfactory to the Purchaser.

 

		(e)	Corporate
                                         Consents. The Company shall have obtained the consent of its Board of Directors authorizing
                                         the execution, delivery and performance of this Agreement and the issuance and sale of
                                         the Private Placement Warrants.

 

		5.	Conditions
                                         of the Company’s Obligations. The obligations of the Company to the Purchaser
                                         under this Agreement are subject to the fulfillment, on or before each Closing Date,
                                         of each of the following conditions:

 

		(a)	Representations
                                         and Warranties. The representations and warranties of the Purchaser contained in
                                         Section 3 shall be true and correct at and as of such Closing Date as though then
                                         made.

 

		(b)	Performance.
                                         The Purchaser shall have performed and complied with all agreements, obligations and
                                         conditions contained in this Agreement that are required to be performed or complied
                                         with by the Purchaser on or before such Closing Date.

 

		(c)	No
                                         Injunction. No litigation, statute, rule, regulation, executive order, decree, ruling
                                         or injunction shall have been enacted, entered, promulgated or endorsed by or in any
                                         court or governmental authority of competent jurisdiction or any self-regulatory organization
                                         having authority over the matters contemplated hereby, which prohibits the consummation
                                         of any of the transactions contemplated by this Agreement.

 

    - 5 -

     

    

 

		(d)	Registration
                                         Rights Agreement. The Company shall have entered into a registration rights agreement
                                         on terms satisfactory to the Company.

 

		6.	Termination.
                                         This Agreement may be terminated at any time after December 31, 2021, upon the election
                                         by either the Company or the Purchaser solely as to itself upon written notice to the
                                         other parties if the closing of the Public Offering does not occur prior to such date.

 

		7.	Survival
                                         of Representations and Warranties. All of the representations and warranties contained
                                         herein shall survive each Closing Date.

 

		8.	Definitions.
                                         Terms used but not otherwise defined in this Agreement shall have the meaning assigned
                                         to such terms in the Registration Statement.

 

		9.	Miscellaneous.

 

		(a)	Successors
                                         and Assigns. Except as otherwise expressly provided herein, all covenants and agreements
                                         contained in this Agreement by or on behalf of any of the parties hereto shall bind and
                                         inure to the benefit of the respective successors of the parties hereto whether so expressed
                                         or not. Notwithstanding the foregoing or anything to the contrary herein, the parties
                                         may not assign this Agreement without the prior written consent of the other party hereto,
                                         other than assignments by the Purchaser to affiliates thereof.

 

		(b)	Severability.
                                         Whenever possible, each provision of this Agreement shall be interpreted in such manner
                                         as to be effective and valid under applicable law, but if any provision of this Agreement
                                         is held to be prohibited by or invalid under applicable law, such provision shall be
                                         ineffective only to the extent of such prohibition or invalidity, without invalidating
                                         the remainder of this Agreement.

 

		(c)	Counterparts.
                                         This Agreement may be executed simultaneously in two or more counterparts, none of which
                                         need contain the signatures of more than one party, but all such counterparts taken together
                                         shall constitute one and the same agreement.

 

		(d)	Descriptive
                                         Headings; Interpretation. The descriptive headings of this Agreement are inserted
                                         for convenience only and do not constitute a substantive part of this Agreement. The
                                         use of the word “including” in this Agreement shall be by way of example
                                         rather than by limitation.

 

		(e)	Governing
                                         Law. This Agreement shall be deemed to be a contract made under the laws of the State
                                         of New York and for all purposes shall be construed in accordance with the internal laws
                                         of the State of New York, without regard to the conflicts of laws principles thereof.

 

		(f)	Amendments.
                                         This Agreement may not be amended, modified or waived as to any particular provision,
                                         except by a written instrument executed by all parties hereto.

 

 

[Signature
page follows]

 

    - 6 -

     

    

 

IN
WITNESS WHEREOF, the parties hereto have executed this Agreement to be effective as of the date first set forth above. 

 

	 	COMPANY:
	 	BIOTECH
    ACQUISITION COMPANY
	 	 
	 	By:	 
	 	 	Name:	Michael
    Shleifer
	 	 	Title:	Chief
Executive Officer and 

        Chairman
        of the Board

	 	 
	 	 
	 	PURCHASER:
	 	BIOTECH
    SPONSOR LLC
	 	 
	 	By:	 
	 	 	Name:	Michael
    Shleifer
	 	 	Title:	Authorized
    Person

 

    - 7 -

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00319-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00319-of-00352.parquet"}]]